What Are The Risk Factors For Sonnet BioTherapeutics Holdings Inc. (SONN)?

As of Thursday close, Sonnet BioTherapeutics Holdings Inc.’s (NASDAQ:SONN) stock was up $0.01, moving up 3.08 percent to $0.26. The average number of shares traded per day over the past five days has been 898,320 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0386 fall in that time frame. In the last twenty days, the average volume was 1,184,620, while in the previous 50 days, it was 8,627,168.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Since last month, SONN stock retreated -38.93%. Shares of the company fell to $0.2352 on 05/12/22, the lowest level in the past month. A 52-week high of $2.07 was reached on 03/16/22 after having rallying from a 52-week low of $0.24. Since the beginning of this year, SONN’s stock price has dropped by -37.62% or -$0.1554, and marked a new high 3 times. However, the stock has declined by -87.55% since its 52-week high.

Sonnet BioTherapeutics Holdings Inc. (SONN) last reported insider trading activity 338 days ago on Jun 09. Kenney Richard T, the Chief Medical Officer of the company, purchased of 15,000 shares for $1.54 on Jun 09. It resulted in a $23,100 investment by the insider. Mohan Pankaj added 32,000 shares at an average price of $1.55 on Jun 09. The insider now owns 354,266 shares following the transaction. On May 19, Chief Medical Officer Kenney Richard T bought 10,000 shares at $1.55 apiece. The transaction was valued at $15,500.

Valuation Metrics

The stock’s beta is 0.71. Besides these, the trailing price-to-sales (P/S) ratio of 26.60, the price-to-book (PB) ratio of 0.95.

Financial Health

Based on annual data, SONN earned $0.48 million in gross profit and brought in $0.48 million in revenue.

According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SONN’s revenue rose 100.0% to $0.13 million during the quarter, while net income inched up to $100000.0. While analysts expected Sonnet BioTherapeutics Holdings Inc. to report -$0.22 quarterly earnings, the actual figure was -$0.17 per share, beating the consensus estimate by 22.70%. During the quarter, the company generated -$8.18 million in EBITDA. The liabilities of Sonnet BioTherapeutics Holdings Inc. were 6.51 million at the end of its most recent quarter ended September 29, and its total debt was $0.13 million. The value of shareholders’ equity is $60.59 million.

Technical Picture

This quick technical analysis looks at Sonnet BioTherapeutics Holdings Inc.’s (SONN) price momentum. With a historical volatility rate of 58.04%, the RSI 9-day stood at 28.52% on 12 May.

With respect to its five-day moving average, the current Sonnet BioTherapeutics Holdings Inc. price is down by -13.03% percent or -$0.0386. At present, SONN shares trade -28.58% below its 20-day simple moving average and -45.17% percent below its 100-day simple moving average. However, the stock is currently trading approximately -26.60% below its SMA50 and -76.99% below its SMA200.

Stochastic coefficient K was 13.12% and Stochastic coefficient D was 10.56%, while ATR was 0.0283. Given the Stochastic reading of 21.89% for the 14-day period, the RSI (14) reading has been calculated as 34.13%. As of today, the MACD Oscillator reading stands at -0.0235, while the 14-day reading stands at -0.0312.

Analyst Ratings

Sonnet BioTherapeutics Holdings Inc. (SONN) has been rated Buy by analysts. According to 0 brokerage firms, SONN is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Sonnet BioTherapeutics Holdings Inc. stock as buy, with 2 recommending it as overweight.

With a median target price of $2.25, the current consensus forecast for the stock is $2.00 – $2.50. Based on these forecasts, analysts predict Sonnet BioTherapeutics Holdings Inc. (SONN) will achieve an average price target of $2.25.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Hot Topics

Related Articles